Multiple Myeloma Medical Services in China

Multiple Myeloma (MM) is a malignant plasma cell neoplasm characterized by clonal proliferation of abnormal plasma cells in the bone marrow, leading to end-organ damage—including hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB criteria). It accounts for approximately 10% of all hematologic malignancies and predominantly affects older adults, with median age at diagnosis around 69 years. While still considered incurable in most cases, advances in immunomodulatory drugs (e.g., lenalidomide), proteasome inhibitors (e.g., bortezomib, carfilzomib), monoclonal antibodies (e.g., daratumumab), and autologous stem cell transplantation have significantly improved progression-free and overall survival. Risk stratification relies on cytogenetics (e.g., del(17p), t(4;14)), ISS/R-ISS staging, and minimal residual disease (MRD) assessment via next-generation flow cytometry or sequencing.

China offers compelling advantages for MM treatment: its top-tier oncology centers—such as Peking University Cancer Hospital and Shanghai Ruijin Hospital—boast internationally trained hematologists, FDA- and NMPA-approved novel agents, and robust clinical trial participation. Advanced diagnostics including whole-exome sequencing and MRD monitoring are routinely integrated into care pathways. Five-year overall survival rates now exceed 55–60% in eligible transplant candidates, aligning closely with Western benchmarks. Crucially, treatment costs in China are typically 40–60% lower than in the US or EU, without compromising protocol fidelity or safety standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients—handling hospital referrals, visa support, real-time translation, transparent itemized pricing, and end-to-end coordination from initial consultation through follow-up care.

Treatment Options & Itemized Cost Breakdown: Multiple Myeloma (Hematology/Oncology)

Non-Surgical/Medical Therapy (First-Line & Maintenance)

*Eligibility*: Newly diagnosed, relapsed/refractory, or transplant-ineligible patients; requires confirmed monoclonal protein, bone marrow plasma cell ≥10%, and end-organ damage (CRAB criteria).

• •Induction Therapy (3–4 cycles)

- *VRd regimen (Bortezomib + Lenalidomide + Dexamethasone)*: ¥42,000–¥54,000/cycle → $5,820–$7,500 - *Daratumumab-based (e.g., D-Rd)*: ¥68,000–¥82,000/cycle → $9,430–$11,370

• •Supportive Care & Monitoring

- Quantitative immunoglobulins + SPEP + UPEP: ¥480 → $67 - Bone marrow biopsy with flow cytometry & FISH: ¥2,100 → $291 - Whole-body low-dose CT or PET/CT (per scan): ¥3,800–¥5,200 → $527–$721

Surgical/Procedural Interventions

*Eligibility*: Symptomatic spinal cord compression, pathologic vertebral fracture unresponsive to radiotherapy, or impending limb-threatening bone lesion. Performed by Orthopedic Oncology or Interventional Radiology.

• •Vertebroplasty/Kyphoplasty (per level): ¥18,000–¥24,500 → $2,500–$3,400
• •Stabilization Surgery (spinal fusion, tumor resection): ¥65,000–¥92,000 → $9,010–$12,750
• •*Preoperative Workup (mandatory)*: CBC, renal panel, coagulation, ECG, chest X-ray, MRI spine: ¥1,950 → $270

Special/Complex Condition Management

• •Autologous Stem Cell Transplant (ASCT): Eligible for fit patients <70 years with adequate organ function.

- Apheresis + cryopreservation: ¥8,200 → $1,140 - High-dose Melphalan conditioning + inpatient care (14–21 days): ¥48,000–¥63,000 → $6,650–$8,730

• •CAR-T Therapy (Cilta-cel or BCMA-targeted): Approved for ≥4 prior lines; requires lymphodepletion.

Quick Selection Guide

• •<65 years, fit, no major comorbidities: VRd induction → ASCT → Lenalidomide maintenance. *Total estimated first-year cost: $32,000–$41,000*.
• •65–75 years, moderate renal impairment: Rd or Daratumumab-Rd. Avoid ASCT; prioritize renal-sparing regimens. *Annual cost: $18,000–$26,000*.
• •>75 years or frail (ADL-dependent, eGFR <30 mL/min): Once-weekly low-dose Rd or Daratumumab monotherapy. Minimize toxicity; emphasize supportive care. *Annual cost: $12,000–$19,000*.
• •Relapsed/refractory after ≥3 lines: CAR-T if accessible and lymphocyte count ≥100/μL; otherwise, Selinexor + Bortezomib + Dexamethasone (¥31,000/cycle → $4,300).